HCA Healthcare (HCA)
(Delayed Data from NYSE)
$415.54 USD
+9.06 (2.23%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $415.66 +0.12 (0.03%) 7:16 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$415.54 USD
+9.06 (2.23%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $415.66 +0.12 (0.03%) 7:16 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
Zacks News
Why Prudent Investors Are Snapping Up Ensign (ENSG) Stock Now
by Zacks Equity Research
Ensign (ENSG) expects to witness strong acquisition opportunities in the fall of this year.
Here's Why Encompass Health (EHC) Stock is a Strong Buy Now
by Zacks Equity Research
Encompass Health's (EHC) focus on boosting the number of licensed beds and hospitals will likely enhance market density and build scale.
Is HCA (HCA) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), HCA (HCA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Is Haemonetics (HAE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Haemonetics (HAE) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
Universal Health (UHS) Gains From Solid Segmental Performance
by Zacks Equity Research
Universal Health (UHS) gains from the uptrend in revenue growth, which in turn, is derived from expanding patient volumes. A credible financial position drives its expansion endeavors.
HCA Healthcare (HCA) Rises 24% in a Year: More Room to Run?
by Zacks Equity Research
HCA Healthcare (HCA) is well-poised for growth on the back of improved patient occupancy levels, effective telehealth services suite and solid cash-generating abilities.
Cigna (CI) Unit Ties Up to Offer Digital Health Tool to Clients
by Zacks Equity Research
Cigna's (CI) division, Cigna Healthcare, teams up with Virgin Pulse to make an effective digital health solution available to its clients, who can now improve their well-being.
The Zacks Analyst Blog Highlights JPMorgan Chase, Salesforce, Abbott Laboratories, HCA Healthcare and General Motors
by Zacks Equity Research
JPMorgan Chase, Salesforce, Abbott Laboratories, HCA Healthcare and General Motors are included in this Analyst Blog.
Top Stock Reports for JPMorgan Chase, Salesforce & Abbott Laboratories
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Salesforce, Inc. (CRM) and Abbott Laboratories (ABT).
Brookdale Senior (BKD) Shares Jump 18.7% Since Q2 Earnings Beat
by Zacks Equity Research
Brookdale Senior (BKD) expects adjusted EBITDA to be within the $73-$78 million range in the third quarter.
The Joint (JYNT) Reaches 900th Clinic Mark With New Texas Unit
by Zacks Equity Research
The Joint (JYNT) moves from the 800th to the 900th clinic milestone in less than a year.
4 Sector ETFs & Stocks to Play Despite Soft July Jobs Data
by Sanghamitra Saha
The U.S. economy added 187, 000 jobs in July of 2023, below market expectations of 200, 000.
Community Health (CYH) Q2 Earnings Top on Rising Admissions
by Zacks Equity Research
Community Health (CYH) expects net operating revenues in the range of $12,200 million-$12,600 million for 2023.
Pediatrix (MD) Q2 Earnings Meet Estimates, Revenues Up Y/Y
by Zacks Equity Research
Pediatrix (MD) reiterates adjusted EBITDA guidance in the range of $235-$245 million for 2023 compared with $241 million in 2022.
Humana (HUM) Q2 Earnings Beat on Strong Individual MA Unit
by Zacks Equity Research
Humana's (HUM) Q2 results gain from strong pharmacy revenues and revenue growth within the Insurance segment, partly offset by higher benefits expenses.
HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2023 EPS View
by Zacks Equity Research
HCA Healthcare's (HCA) Q2 results benefit from improving patient volumes and surgeries. However, rising expenses acted as a partial offset.
Compared to Estimates, HCA (HCA) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for HCA (HCA) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
HCA Healthcare (HCA) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 0.23% and 1.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights KB Home, Caterpillar, Walmart, HCA Healthcare and Monolithic Power
by Zacks Equity Research
KB Home, Caterpillar, Walmart, HCA Healthcare and Monolithic Power have been highlighted in this Screen of The Week article.
5 Dividend Stocks With Strong Growth Prospects to Buy
by Sweta Killa
KB Home (KBH), Caterpillar (CAT), Walmart (WMT), HCA Healthcare (HCA) and Monolithic Power (MPWR) could be compelling dividend picks for investors.
Will Higher Costs Affect HCA Healthcare's (HCA) Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter results are likely to reflect increased patient volumes, occupancy rate and cost of supplies.
Philips (PHG) Q2 Earnings Beat Estimates, Revenue Rise Y/Y
by Zacks Equity Research
Philips' (PHG) second-quarter results benefit from robust performances by the Diagnosis & Treatment and the Connected Care businesses.
Investors Increasingly Betting on Soft Landing but the Fed Will Throw Cold Water
by Mayur Thaker
If the Fed continues to hike despite softening inflation and economic fundamentals, recession odds increase.
Select Medical (SEM) Expects Q2 Adjusted EBITDA to Jump 21% Y/Y
by Zacks Equity Research
Select Medical's (SEM) strong second-quarter 2023 guidance highlights improving performance in all four segments.
Horace Mann (HMN) Estimates Q2 Cat Loss Between $41M & $43M
by Zacks Equity Research
Horace Mann (HMN) estimates second-quarter catastrophe loss of $41-$43 million pre-tax, which is expected to contribute 26 to 27 points to the second-quarter combined ratio and weigh on the bottom line.